{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:54:00Z","timestamp":1787460840124,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.idc.2004.04.006","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:30Z","timestamp":1113836010000},"page":"603-619","source":"Crossref","is-referenced-by-count":23,"title":["Beta-lactam antibiotics: Newer formulations and newer agents"],"prefix":"10.1016","volume":"18","author":[{"given":"Stanley I","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2004.04.006_BIB1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.43.5.1170","article-title":"In vitro activities of the potent, broad-spectrum carbapenem MK-0826 against broad-spectrum \u03b2-lactamase- and extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates","volume":"43","author":"Kohler","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB2","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1128\/AAC.46.11.3506-3511.2002","article-title":"Pharmacokinetics of ertapenem in healthy young volunteers","volume":"46","author":"Majumdar","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0149-2918(02)85044-5","article-title":"Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone","volume":"24","author":"Legua","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.idc.2004.04.006_BIB4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jac\/dkg404","article-title":"Ertapenem, the first of a new group of carbapenems","volume":"52","author":"Shah","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/AAC.45.6.1860-1867.2001","article-title":"In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB6","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1128\/AAC.44.9.2389-2394.2000","article-title":"Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections","volume":"44","author":"Goldstein","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0732-8893(02)00380-2","article-title":"Use of surrogate antimicrobial agents to predict susceptibility to ertapenem","volume":"43","author":"Friedland","year":"2002","journal-title":"Diagn Microbial Infect Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/339543","article-title":"The Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults","volume":"34","author":"Ortiz-Ruiz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0149-2918(02)80078-9","article-title":"A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for treatment of hospitalized adults with community-acquired pneumonia","volume":"24","author":"Vetter","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.idc.2004.04.006_BIB10","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/AAC.46.9.2895-2900.2002","article-title":"Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study","volume":"46","author":"Tomera","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0090-4295(02)01664-3","article-title":"A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults","volume":"60","author":"Jimenez-Cruz","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.idc.2004.04.006_BIB12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00000658-200302000-00013","article-title":"Ertapenem versus piperacillin\/tazobactam in the treatment of complicated intra-abdominal infections","volume":"237","author":"Solomkin","year":"2003","journal-title":"Ann Surg"},{"key":"10.1016\/j.idc.2004.04.006_BIB13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1086\/340348","article-title":"Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study","volume":"34","author":"Graham","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/S1064744903000048","article-title":"Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized double-blind study","volume":"11","author":"Roy","year":"2003","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.idc.2004.04.006_BIB15","first-page":"145","article-title":"Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers","volume":"23","author":"Li","year":"1997","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.idc.2004.04.006_BIB16","first-page":"265","article-title":"Cefditoren pivoxil","volume":"36","author":"Kuti","year":"2001","journal-title":"Formulary"},{"key":"10.1016\/j.idc.2004.04.006_BIB17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0399-077X(05)80869-8","article-title":"Pharmacokinetic properties of new oral cephalosporins","volume":"22","author":"Kneer","year":"1992","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.idc.2004.04.006_BIB18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003495-200262020-00006","article-title":"Cefditoren pivoxil","volume":"62","author":"Darkes","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.idc.2004.04.006_BIB19","series-title":"Programs and abstracts of the 40th annual interscience conference on antimicrobial agents and chemotherapy","article-title":"Effect of an H2 receptor antagonist or an antacid on the pharmacokinetics of cefditoren","author":"Mayer","year":"2000"},{"key":"10.1016\/j.idc.2004.04.006_BIB20","series-title":"Spectracef (cefditoren) package insert","author":"TAP Pharmaceuticals","year":"2001"},{"key":"10.1016\/j.idc.2004.04.006_BIB21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0009-9236(02)17636-3","article-title":"Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil","volume":"73","author":"Brass","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.idc.2004.04.006_BIB22","series-title":"Programs and abstracts of the 40th annual interscience conference on antimicrobial agents and chemotherapy","article-title":"Effect of renal impairment on the pharmacokinetics of cefditoren","author":"Mulford","year":"2000"},{"key":"10.1016\/j.idc.2004.04.006_BIB23","series-title":"Programs and abstracts of the 41st annual interscience conference on antimicrobial agents and chemotherapy","article-title":"Effect of hepatic impairment on the pharmacokinetics of cefditoren","author":"Mayer","year":"2001"},{"key":"10.1016\/j.idc.2004.04.006_BIB24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0732-8893(91)90068-Q","article-title":"In vitro activity of a new cephalosporin ME-1206 compared with other agents","volume":"14","author":"Chin","year":"1991","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB25","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1128\/AAC.43.8.1901","article-title":"Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 USA surveillance study","volume":"43","author":"Jacobs","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/dkf076","article-title":"Activity of cefditoren against respiratory pathogens","volume":"50","author":"Clark","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 8","key":"10.1016\/j.idc.2004.04.006_BIB27","first-page":"60","article-title":"A multicenter comparison of cefditoren pivoxil and penicillin VK","volume":"22","author":"Kaplan","year":"2001","journal-title":"J Respir Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB28","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0149-2918(02)80083-2","article-title":"Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study","volume":"24","author":"van Zyl","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.idc.2004.04.006_BIB29","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0149-2918(02)80084-4","article-title":"A comparison of cefditoren pivoxil and amoxicillin\/clavulanate for the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study","volume":"24","author":"Fogarty","year":"2002","journal-title":"Clin Ther"},{"issue":"Suppl 8","key":"10.1016\/j.idc.2004.04.006_BIB30","first-page":"69","article-title":"A double-blind, randomized study of cefditoren versus cefuroxime for acute exacerbations of chronic bronchitis (AECB)","volume":"22","author":"Henry","year":"2001","journal-title":"J Respir Dis"},{"issue":"Suppl 8","key":"10.1016\/j.idc.2004.04.006_BIB31","first-page":"75","article-title":"Treating acute exacerbations of chronic bronchitis","volume":"22","author":"Ramirez","year":"2001","journal-title":"J Respir Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB32","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0149-2918(02)80024-8","article-title":"Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400mg bid with either cefuroxime 250 mg bid or cefadroxil 500 mg bid for the treatment of uncomplicated skin and skin-structure infections","volume":"24","author":"Bucko","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.idc.2004.04.006_BIB33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00003495-198122050-00001","article-title":"Amoxycillin\/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use","volume":"22","author":"Brogden","year":"1981","journal-title":"Drugs"},{"key":"10.1016\/j.idc.2004.04.006_BIB34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/j.1875-9114.1984.tb03333.x","article-title":"Amoxicillin and potassium clavulanate: an antibiotic combination: mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects","volume":"4","author":"Weber","year":"1984","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2004.04.006_BIB35","first-page":"591","article-title":"Amoxicillin-potassium clavulanate, a \u03b2-lactamase-resistant antibiotic combination","volume":"3","author":"Stein","year":"1984","journal-title":"Clin Pharm"},{"key":"10.1016\/j.idc.2004.04.006_BIB36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/106002808501900601","article-title":"Amoxicillin-potassium clavulanate: a novel \u03b2-lactamase inhibitor","volume":"19","author":"Smith","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.idc.2004.04.006_BIB37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2165\/00003495-199039020-00008","article-title":"Amoxicillin\/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use","volume":"39","author":"Todd","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.idc.2004.04.006_BIB38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.14.5.650","article-title":"Clavulanic acid, a novel inhibitor of \u03b2-lactamases","volume":"14","author":"Neu","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB39","first-page":"51","article-title":"Augmentin: absorption, excretion and pharmacokinetic studies in man","volume":"76","author":"Jackson","year":"1984","journal-title":"Postgrad Med"},{"key":"10.1016\/j.idc.2004.04.006_BIB40","series-title":"Augmentin XR (amoxicillin-clavulanate) package insert","author":"GlaxoSmithKline","year":"2003"},{"key":"10.1016\/j.idc.2004.04.006_BIB41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0149-2918(01)80061-8","article-title":"The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin\/clavulanate","volume":"23","author":"Kaye","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.idc.2004.04.006_BIB42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/AAC.22.3.353","article-title":"Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination","volume":"22","author":"Adam","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/12.3.273","article-title":"Amoxycillin\/clavulanic acid: the effect of probenecid","volume":"12","author":"Staniforth","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB44","first-page":"99","article-title":"Amoxicillin-clavulanic acid (Augmentin)","volume":"26","year":"1984","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.idc.2004.04.006_BIB45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.24.1.31","article-title":"In vitro evaluation of Augmentin by both microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits","volume":"24","author":"Fuchs","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006454-199901000-00002","article-title":"Acute otitis media: management and surveillance in an era of pneumococcal resistance: report from the Drug-Resistant S. pneumoniae Therapeutic Working Group","volume":"18","author":"Dowell","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2004.04.006_BIB47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0732-8893(97)00195-8","article-title":"Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season","volume":"29","author":"Thornsberry","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB48","first-page":"1647","article-title":"Resistant pneumococci: protecting patients through judicious use of antibiotics","volume":"55","author":"Dowell","year":"1997","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.idc.2004.04.006_BIB49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00006454-199603000-00015","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in otitis media","volume":"15","author":"Craig","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2004.04.006_BIB50","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00006454-199707000-00014","article-title":"Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media","volume":"16","author":"Seikel","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2004.04.006_BIB51","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/AAC.41.9.1926","article-title":"Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies","volume":"41","author":"Lister","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00006454-200109000-00002","article-title":"Bacteriologic and clinical efficacy of high dose amoxicillin\/clavulanate in children with acute otitis media","volume":"20","author":"Dagan","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2004.04.006_BIB53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00006454-200002000-00002","article-title":"Bacteriologic and clinical efficacy of amoxicillin\/clavulanate vs. azithromycin in acute otitis media","volume":"19","author":"Dagan","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2004.04.006_BIB54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/00006454-199810000-00041","article-title":"Safety and tolerability of a new formulation (90 mg\/kg\/day divided every 12h) of amoxicillin\/clavulanate (Augmentin) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae","volume":"17","author":"Bottenfield","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2004.04.006_BIB55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mhn.2000.107873","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis","volume":"123","author":"Sinus and Allergy Health Partnership","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.idc.2004.04.006_BIB56","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"American Thoracic Society","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.idc.2004.04.006_BIB57","first-page":"369","article-title":"Cefepime: the next generation?","volume":"17","author":"Sanders","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4065\/74.2.187","article-title":"The cephalosporins","volume":"74","author":"Marshall","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.idc.2004.04.006_BIB59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.7164\/antibiotics.39.1092","article-title":"Synthesis and structure activity relationships of a new series of cephalosporins, BMY-28142 and related compounds","volume":"39","author":"Naito","year":"1986","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.idc.2004.04.006_BIB60","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.36.3.552","article-title":"Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects","volume":"36","author":"Barbhaiya","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB61","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/AAC.34.6.1118","article-title":"Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses","volume":"34","author":"Barbhaiya","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/j.1552-4604.1990.tb03569.x","article-title":"Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects","volume":"30","author":"Barbhaiya","year":"1990","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.idc.2004.04.006_BIB63","first-page":"124","article-title":"Cefepime versus ceftriaxone: a tolerance study by intramuscular injection","volume":"15","author":"Gubbelmans","year":"1990","journal-title":"Drug Ther Res"},{"key":"10.1016\/j.idc.2004.04.006_BIB64","series-title":"Maxipime (cefepime) package insert","author":"Bristol-Myers Squibb","year":"1996"},{"key":"10.1016\/j.idc.2004.04.006_BIB65","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/jac\/25.6.959","article-title":"Cefepime concentrations in bronchial mucosa and serum after a single 2 gram intravenous dose","volume":"25","author":"Chadha","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/j.1875-9114.1991.tb02644.x","article-title":"Analysis of cefepime tissue penetration into human appendix","volume":"11","author":"Okamoto","year":"1991","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2004.04.006_BIB67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/AAC.36.2.453","article-title":"Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid","volume":"36","author":"Kalman","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB68","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/AAC.39.4.937","article-title":"Prospective randomised comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children","volume":"39","author":"Saez-Llorens","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB69","first-page":"68","article-title":"Disposition of the cephalosporin cefepime in normal and renally impaired subjects","volume":"19","author":"Barbhaiya","year":"1991","journal-title":"Diagn Metab Dispos"},{"key":"10.1016\/j.idc.2004.04.006_BIB70","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1177\/106002809603001211","article-title":"Cefepime: a fourth generation parenteral cephalosporin","volume":"30","author":"Wynd","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idc.2004.04.006_BIB71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.27.2.207","article-title":"Comparison of a new cephalosporin, BMY-28142, with other broad spectrum beta-lactam antibiotics","volume":"27","author":"Kessler","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/17.4.453","article-title":"In vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142, and other antibiotics against nosocomially important isolates from cancer patients","volume":"17","author":"Rolston","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB73","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1128\/AAC.28.1.58","article-title":"In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum","volume":"28","author":"Conrad","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2004.04.006_BIB74","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/clinids\/23.3.454","article-title":"Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species","volume":"23","author":"Sanders","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2004.04.006_BIB75","first-page":"10","article-title":"Susceptibility of recent bacterial isolates from the cefepime clinical trials in the United States","volume":"95","author":"Kessler","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2004.04.006_BIB76","first-page":"67","article-title":"Safety of cefepime: a new extended-spectrum cephalosporin antibiotic","volume":"95","author":"Neu","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2004.04.006_BIB77","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517658","article-title":"Rapid emergence of resistance to cefepime during treatment","volume":"26","author":"Acar","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552004000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552004000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:08:05Z","timestamp":1735672085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552004000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0891552004000704"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2004.04.006","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}